Infliximab dose escalation not uncommon during first year in RA

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1520, 2006-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Infliximab, etanercept in RA discussed

By  

Inpharma, Vol. 1, Iss. 1325, 2002-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

First-year cost savings may be greater with etanercept in RA

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 482, 2005-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

First-year cost savings may be greater with etanercept in RA

By  

Inpharma, Vol. 1, Iss. 1498, 2005-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Crossover Versus Parallel Designs: Dose-Escalation Design Comparisons for First-In-Human Studies

By Yan Zhiwu   Hosmane Balakrishna   Locke Charles  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 4, 2013-07 ,pp. : 804-817

Taylor & Francis Ltd

Access to resources Recommend Favorite

An Adaptive First in Man Dose-Escalation Study of NGX267: Statistical, Clinical, and Operational Considerations

By Ivanova Anastasia  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 2, 2009-03 ,pp. : 247-255

Taylor & Francis Ltd

Access to resources Recommend Favorite